Inspired by professional human interpreters, we utilize a novel data-driven read-write strategy to balance the translation quality and latency. To address the challenge of translating in-domain terminologies, CLASI employs a multi-modal retrieving module to obtain relevant information to augment the translation. Supported by LLMs, our approach can generate error-tolerated translation by considering the input audio, historical context, and retrieved information. Experimental results show that our system outperforms other systems by significant margins. Aligned with professional human interpreters, we evaluate CLASI with a better human evaluation metric, valid information proportion (VIP), which measures the amount of information that can be successfully conveyed to the listeners. In the real-world scenarios, where the speeches are often disfluent, informal, and unclear, CLASI achieves VIP of 81.3% and 78.0% for Chinese-to-English and English-to-Chinese translation directions, respectively. In contrast, state-of-the-art commercial or open-source systems only achieve 35.4% and 41.6%. On the extremely hard dataset, where other systems achieve under 13% VIP, CLASI can still achieve 70% VIP.

Higher expression of nine genes may help identify people with systemic lupus erythematosus (SLE) who will respond to treatment with Stelara (ustekinumab) -- an approved therapy in inflammatory disorders but not in SLE. At the 2019 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, being held in Atlanta Nov. 8-13, Janssen is presenting evidence of reduced SLE disease activity with Stelara, as well as a tool to predict benefits in clinical trials. Stelara works by blocking interleukin (IL)-12 and IL-23, two pro-inflammatory molecules. It is approved in the U.S. for the treatment of psoriasis and psoriatic arthritis, as well as Crohn's disease and ulcerative colitis, which are two forms of inflammatory bowel disease. Results from a Phase 2 trial (NCT02349061) showed that Stelara reduced SLE disease activity and severe flares, among other benefits, compared with a placebo.